Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,678 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.
Jiang Y, Song L, Lin Y, Nowialis P, Gao Q, Li T, Li B, Mao X, Song Q, Xing C, Zheng G, Huang S, Jin L. Jiang Y, et al. Among authors: zheng g. Oncogene. 2023 May;42(20):1672-1684. doi: 10.1038/s41388-023-02679-6. Epub 2023 Apr 5. Oncogene. 2023. PMID: 37020040 Free PMC article.
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice.
Khan S, Kellish P, Connis N, Thummuri D, Wiegand J, Zhang P, Zhang X, Budamagunta V, Hua N, Yang Y, De U, Jin L, Zhang W, Zheng G, Hromas R, Hann C, Zajac-Kaye M, Kaye FJ, Zhou D. Khan S, et al. Among authors: zheng g. Cell Death Discov. 2023 Jan 2;9(1):1. doi: 10.1038/s41420-022-01296-8. Cell Death Discov. 2023. PMID: 36588105 Free PMC article.
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.
Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe CD, Zheng G, Trevino JG, Zhou D. Thummuri D, et al. Among authors: zheng g. Mol Cancer Ther. 2022 Jan;21(1):184-192. doi: 10.1158/1535-7163.MCT-21-0474. Epub 2021 Oct 19. Mol Cancer Ther. 2022. PMID: 34667112 Free PMC article.
Overcoming Cancer Drug Resistance Utilizing PROTAC Technology.
Burke MR, Smith AR, Zheng G. Burke MR, et al. Among authors: zheng g. Front Cell Dev Biol. 2022 Apr 25;10:872729. doi: 10.3389/fcell.2022.872729. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35547806 Free PMC article. Review.
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.
Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, Liu Y, Maharjan CK, Patel UM, De U, Carelock ME, Tithi TI, Li X, Shaffer DR, Guertin KR, Zhuang H, Moser E, Smalley KSM, Lv D, Zhou D, Zheng G, Zhang W. Wang L, et al. Among authors: zheng g. J Exp Med. 2024 Mar 4;221(3):e20231519. doi: 10.1084/jem.20231519. Epub 2024 Feb 9. J Exp Med. 2024. PMID: 38334978 Free PMC article.
5,678 results